FDA grants emergency use authorization for Johnson & Johnson COVID-19 vaccine

The Food and Drug Administration on Saturday authorized Johnson & Johnson's single-dose COVID-19 vaccine for emergency use, which means there will soon be three effective shots available for Americans.

The Johnson & Johnson candidate registered a 72 percent efficacy rate in the U.S. clinical trial. That falls short of the roughly 95 percent rates seen in the Pfizer-BioNTech and Moderna trials, but, The New York Times notes, experts are still very pleased with Johnson & Johnson's results, especially since it also showed 85 percent efficacy against severe COVID-19 infections, and 100 percent efficacy against hospitalizations and deaths, suggesting it will be a crucial tool in the fight to end the pandemic.

Dr. Anthony Fauci, the government's top infectious disease expert, told the Times people shouldn't get wrapped up in the numbers and instead "accept the fact that now you have three highly effective vaccines. Period." And Dr. Danny Avula, the vaccine coordinator for Virginia, said he's "super-pumped about this," adding that the lack of hospitalizations and deaths among vaccinated trial volunteers is "all I need to hear."

The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up

Plus, Johnson & Johnson's vaccine requires just one dose for full inoculation and can be stored at standard refrigeration temperatures for three months, which will help states speed up their vaccination drives and make distribution easier. All told, Johnson & Johnson has pledged to provide the U.S. with 100 million doses by June, but four million doses should be ready to go as soon as possible now that the FDA has signed off, with another 16 million available by the end of the March. Read more at The New York Times.